efficacy and safety of Gemcitabine plus nab-paclitaxel in unresectable pancreas cancer

efficacy and safety of Gemcitabine plus nab-paclitaxel in unresectable pancreas cancer - Gemcitabine plus nab-paclitaxel treatment for pancreas cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013206

Enrollment

Registered

2014-02-20

Start date

2014-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable pancreas cancer

Interventions

Gemcitabine nab-Paclitaxel endoscopic elastography

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: unresectable pancreas cancer alive more than three months EUS-elastgraphy was performed before the chemotheraphy. pathological diagnosis is invasive ductal carcinoma. GEM+nabPTX regimen is planning as first line chemotherapy.

Exclusion criteria

Exclusion criteria: other malignant diseases Paformance status 3,4 uncontrolable pleural effusion and/or ascites uncontrolable infection uncontrolable DM past treatment history to pancreas cancer

Design outcomes

Primary

Measure	Time frame
response rate	—

Secondary

Measure	Time frame
progression free survival overall survival classification of elastography	—

Countries

Japan

Contacts

Public ContactNoritoshi Kobayashi

Yokohama City University Hospital Clinical Oncology

norikoba@yokohama-cu.ac.jp045-787-2623

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026